RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0

OBJECTIVE: Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 has been rapidly accepted in clinical trials as a standard measure to assess tumor response to therapy and is expected to improve response assessment, especially in genomically defined patients. The impact of RECIST 1.1 was compare...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Nishino, Mizuki, Cardarella, Stephanie, Jackman, David M., Ramaiya, Nikhil H., Rabin, Michael S., Hatabu, Hiroto, Jänne, Pasi A., Johnson, Bruce E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3731976/
https://ncbi.nlm.nih.gov/pubmed/23789698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2214/AJR.12.9668
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky